Clearmind Medicine Commends Executive Order Prioritizing FDA Review of Psychedelic Therapies

On April 20, 2026, Clearmind Medicine Inc. issued a press release responding to a new U.S. Executive Order titled 'Accelerating Medical Treatments for Serious Mental Illness.' The order directs the FDA to prioritize review processes for psychedelic drugs designated as breakthrough therapies and expands patient access pathways, particularly for veterans. Clearmind, a clinical-stage biotech developing non-hallucinogenic neuroplastogens, noted that this regulatory shift aligns with its mission to treat conditions like alcohol use disorder (AUD), PTSD, and depression. The company highlighted that its lead candidate, CMND-100 (MEAI), was recently named in bipartisan U.S. Congressional legislation (H.R. 7091) aimed at expanding veteran access to emerging treatments. Clearmind is currently advancing FDA-approved Phase I/IIa clinical trials for CMND-100 in the treatment of AUD at Yale School of Medicine and Johns Hopkins University. The company views the Executive Order as a significant catalyst for accelerating the development and potential commercialization of its psychedelic-derived therapeutic pipeline.